Head-To-Head Survey: Candel Therapeutics (NASDAQ:CADL) vs. Outlook Therapeutics (NASDAQ:OTLK)

Outlook Therapeutics (NASDAQ:OTLK) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Volatility & Risk

Outlook Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.95, suggesting that its stock price is 195% less volatile than the S&P 500.

Profitability

This table compares Outlook Therapeutics and Candel Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Outlook Therapeutics	N/A	N/A	-160.88%
Candel Therapeutics	N/A	-629.29%	-173.39%

Institutional and Insider Ownership

11.2% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 3.4% of Outlook Therapeutics shares are held by company insiders. Comparatively, 41.6% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Outlook Therapeutics and Candel Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outlook Therapeutics	N/A	N/A	-$58.98 million	($8.94)	-0.23
Candel Therapeutics	$120,000.00	2,432.99	-$37.94 million	($1.73)	-5.20

Candel Therapeutics has higher revenue and earnings than Outlook Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Outlook Therapeutics and Candel Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outlook Therapeutics	0	1	6	0	2.86
Candel Therapeutics	0	0	1	0	3.00

Outlook Therapeutics currently has a consensus target price of $32.73, suggesting a potential upside of 1,489.00%. Candel Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 111.35%. Given Outlook Therapeutics’ higher probable upside, analysts clearly believe Outlook Therapeutics is more favorable than Candel Therapeutics.

About Outlook Therapeutics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.